Please Upload related files below
Fill in below.
Tell us the stocks you own using SnapTrade, and we will keep you informed about class action litigation related to your stocks. We monitor critical case developments that may affect the price of your shares and your possible monetary recovery. SnapTrade only shares the tickers you own and your transaction history, not your account numbers. Using SnapTrade and participating in our monitoring service is free and does not create any attorney-client relationship or obligation on your part.
Don’t miss out on possible monetary recovery - link your account with SnapTrade.
Nyxoah issued a press release on March 25, 2025, “announc[ing] that the U.S. Food and Drug Administration (FDA) has issued an Approvable Letter regarding the Company’s Pre-Market Approval (PMA) application for the Genio® system”, which “means that Nyxoah’s application for marketing the device in the United States substantially meets the requirements of the Federal Food, Drug and Cosmetic Act and the FDA’s PMA implementing regulations . . . , and the FDA will approve the application subject to satisfactory completion of a manufacturing facilities, methods and controls review.” Following Nyxoah’s announcement, analysts projected that Genio’s commercial launch would be delayed pending further review by the FDA.
Following this news, Nyxoah’s stock price fell over 21% on March 26, 2025.